Diversified Trust Co Has $358,000 Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Diversified Trust Co lessened its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 25.9% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,098 shares of the biopharmaceutical company’s stock after selling 384 shares during the period. Diversified Trust Co’s holdings in Alnylam Pharmaceuticals were worth $358,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. SVB Wealth LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the 1st quarter valued at $27,000. Whipplewood Advisors LLC boosted its stake in shares of Alnylam Pharmaceuticals by 208.8% in the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 71 shares in the last quarter. Bessemer Group Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 176.9% in the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 69 shares in the last quarter. Park Square Financial Group LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at $28,000. Finally, Washington Trust Advisors Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 53.5% in the 1st quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 61 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, Director Michael W. Bonney sold 11,250 shares of the stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $450.00, for a total transaction of $5,062,500.00. Following the completion of the sale, the director directly owned 16,804 shares of the company’s stock, valued at approximately $7,561,800. This represents a 40.10% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Yvonne Greenstreet sold 6,979 shares of the stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $453.27, for a total value of $3,163,371.33. Following the sale, the chief executive officer directly owned 56,221 shares of the company’s stock, valued at approximately $25,483,292.67. The trade was a 11.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 75,594 shares of company stock worth $33,968,256 in the last quarter. Company insiders own 1.20% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $454.41 on Wednesday. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75. The stock has a market cap of $59.56 billion, a PE ratio of -183.97 and a beta of 0.32. The stock has a 50-day moving average of $420.78 and a 200-day moving average of $327.63. Alnylam Pharmaceuticals, Inc. has a one year low of $205.87 and a one year high of $484.21.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.86. The company had revenue of $773.69 million during the quarter, compared to analysts’ expectations of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.Alnylam Pharmaceuticals’s revenue was up 17.3% on a year-over-year basis. During the same period in the prior year, the business posted ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Analyst Ratings Changes

ALNY has been the topic of several research reports. Evercore ISI upped their price target on shares of Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the stock an “outperform” rating in a research report on Thursday, September 11th. Oppenheimer upgraded shares of Alnylam Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $490.00 price target on the stock in a research report on Monday, August 4th. Scotiabank upped their price target on shares of Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the stock a “sector outperform” rating in a research report on Friday, August 1st. Royal Bank Of Canada upped their price target on shares of Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the stock an “outperform” rating in a research report on Friday, September 19th. Finally, The Goldman Sachs Group upped their price target on shares of Alnylam Pharmaceuticals from $504.00 to $566.00 and gave the stock a “buy” rating in a research report on Tuesday, September 16th. Twenty-four research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $439.58.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.